Lee S, Chae S, Jang I, Oh S, Kim S, Lee S, et al. B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in patients with liquid tumours: evidence from clinical, in silico, in vitro, and in vivo studies. EBioMedicine. 2024;110:105459 pubmed publisher

Zhao N, Pi R, Nguyen D, Ranganath T, Seiler C, Holmes S, et al. NKp30 and NKG2D contribute to natural killer recognition of HIV-infected cells. bioRxiv. 2024;: pubmed publisher

Fisher J, Doyle A, Graham L, Sonar S, Sale B, Henderson I, et al. XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression. Leukemia. 2023;37:2036-2049 pubmed publisher

Shemesh A, Pickering H, Roybal K, Lanier L. Differential IL-12 signaling induces human natural killer cell activating receptor-mediated ligand-specific expansion. J Exp Med. 2022;219: pubmed publisher

Gonz xe1 lez Ochoa S, Tellez Ba xf1 uelos M, M xe9 ndez Clemente A, Bravo Cuellar A, Hern xe1 ndez Flores G, Palafox Mariscal L, et al. Combination Blockade of the IL6R/STAT-3 Axis with TIGIT and Its Impact on the Functional Activity of NK Cells against Prostate Cancer Cells. J Immunol Res. 2022;2022:1810804 pubmed publisher

Aarsund M, Segers F, Wu Y, Inngjerdingen M. Comparison of characteristics and tumor targeting properties of extracellular vesicles derived from primary NK cells or NK-cell lines stimulated with IL-15 or IL-12/15/18. Cancer Immunol Immunother. 2022;71:2227-2238 pubmed publisher

Makanga D, Da Rin de Lorenzo F, David G, Willem C, Dubreuil L, Legrand N, et al. Genetic and Molecular Basis of Heterogeneous NK Cell Responses against Acute Leukemia. Cancers (Basel). 2020;12: pubmed publisher

Fasbender F, Obholzer M, Metzler S, St xf6 ber R, Hengstler J, Watzl C. Enhanced activation of human NK cells by drug-exposed hepatocytes. Arch Toxicol. 2020;94:439-448 pubmed publisher